|
| Primary information |
|---|
| ID | 10226 |
| Therapeutic ID | Th1030 |
| Protein Name | Interferon gamma-1b |
| Sequence | >Th1030_Interferon_gamma-1b
CYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ
|
| Molecular Weight | 17145.6 |
| Chemical Formula | C761H1206N214O225S6 |
| Isoelectric Point | 9.54 |
| Hydrophobicity | -0.823 |
| Melting point | 61 |
| Half-life | NA |
| Description | Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography.
The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b. |
| Indication/Disease | To treat Chronic granulomatous disease and Osteopetrosis. |
| Pharmacodynamics | IFN gamma stimulates expression of the immunoglobulin heavy chain C gamma 3 and C gamma 2a germline transcripts in B cells. Many components of the antigen presentation pathways are also up-regulated by interferon gamma. It is also a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of type I interferons. Interferon gamma may also help the body regulate the activity of fibroblasts. By directly blocking the multiplication of fibroblasts and inhibiting the production and action of TGF-b, a potent scar-inducing molecule, Interferon gamma-1b may prevent excessive scarring. |
| Mechanism of Action | It binds directly to the type II interferon gamma receptor IFNGR1, leading to a complex of IFNGR1 and IFNGR2. This activates JAK1 and JAK2 kinases which form a STAT1 docking site. This leads to STAT1 phosphorylation, nuclear translocation and initiation of gene transcription of multiple immune-related genes. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| NA |
| Clearance | NA |
| Categories | Amino Acids, Peptides, and Proteins, Biological Factors, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytokines, Immunosuppressive Agents, Intercellular Signaling Peptides and Proteins, Interferon gamma, Interferons, Lymphokines, Macrophage-Activating Factors, Myelosuppressive Agents, Peptides, Proteins |
| Patents Number | US6936695 |
| Date of Issue | 30-Aug-2005 |
| Date of Expiry | 30-Aug-2022 |
| Drug Interaction | NA |
| Target | Interferon gamma receptor 1,Interferon gamma receptor 2 |
| Brand Name | Actimmune |
| Company | InterMune Inc, Hznp Usa, Inc., Horizon Therapeutics USA, Inc. |
| Brand Description | InterMune Inc, Hznp Usa, Inc., Horizon Therapeutics USA, Inc. |
| Prescribed For | Used for reducing the number and severity of infections associated with chronic granulomatous disease. It is also used to delay the progression of severe, life-threatening bone density disease |
| Chemical Name | NA |
| Formulation | Each 0.5 mL of ACTIMMUNE contains 100 mcg (2 million IU) of Interferon gamma-1 b formulated in 20 mg mannitol, 0.36 mg sodium succinate, 0.05 mg polysorbate 20 and Sterile Water for Injection. |
| Physical Appearance | Sterile, clear, colorless solution |
| Route of Administration | Subcutaneous Injection |
| Recommended Dosage | Dose for the treatment of patients with Chronic Granulomatous Disease and severe, malignant osteopetrosis is 50 mcg/m2(1 million IU/m2) for patients whose body surface area is greater than 0.5 m2 and 1.5 mcg/kg/dose for patients whose body surface area is equal to or less than 0.5 m2. |
| Contraindication | Hypersensitivity |
| Side Effects | Diarrhea; fatigue; flu-like symptoms (eg, low-grade fever, chills, general body discomfort); headache; joint pain; muscle pain; nausea; pain, redness, or swelling at the injection site; tiredness; vomiting; weakness. Severe side efects include Severe dizziness and troubled breathing. |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |